New Narcolepsy Medication to Be Priced Competitively, Manufacturer Says
May 4th 2023Despite having a highly differentiated clinical value proposition compared to branded, twice-nightly oxybates, Avadel is pricing Lumryz at $64.67 per gram or around $177,034 annually, which is on par with twice-nightly oxybate products that require chronic, middle-of-the-night awakening.
Study Shows Multiple Infliximab Biosimilar Switches are Effective for Patients with IBD
April 21st 2023A study in Scotland found that multiple successive changes from originator infliximab to biosimilars effective and safe for patients with irritable bowel disease (IBD), irrespective of the number of switches (single, double, and triple).